Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786732 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
A Phase 3 study, sponsored by MedDerm Associates.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT02786732 is a Phase 3 study that was terminated before completion, run by MedDerm Associates. The registered enrollment target is 15 participants.
The verdict
NCT02786732, a Phase 3 study, was terminated before completion, sponsored by MedDerm Associates.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ustekinumab
- BIOLOGICAL 210mg Brodalumab
- BIOLOGICAL 140mg Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02786732
The ClinicalTrials.gov registry entry for NCT02786732 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedDerm Associates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02786732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02786732 about?
NCT02786732 is a clinical study titled "Study to Evaluate Broadlumab vs Placebo and Ustekinumab". The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT02786732?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2012-08. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02786732?
The interventions under investigation include: Placebo (BIOLOGICAL), Ustekinumab (BIOLOGICAL), 210mg Brodalumab (BIOLOGICAL), 140mg Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02786732?
This trial is sponsored by MedDerm Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.